RxDoctor Payments Data

Lorraine Ruchalski, APRN

Nurse Practitioner · Cherry Hill, NJNPI 1295265965

Payments from drug & device makers

$3,461in general payments, 2019–2025

Across 155 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$791
  • Amgen$653
  • Teva Pharmaceuticals USA, Inc.$284
  • Pfizer$37
  • Astellas Pharma US Inc$17
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$3,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,461 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$34,918
Medicare patients
120
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$84,424
JardianceEmpagliflozin60$52,605
FarxigaDapagliflozin Propanediol39$37,653
EliquisApixaban32$31,350
MounjaroTirzepatide16$24,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,329
Repatha SureclickEvolocumab18$18,654
QuliptaAtogepant14$16,940
JanuviaSitagliptin Phosphate17$13,127
XareltoRivaroxaban14$12,963
LinzessLinaclotide15$10,719
Breo ElliptaFluticasone/Vilanterol25$9,814
Advair HfaFluticasone Propion/Salmeterol20$8,662
Fluticasone-SalmeterolFluticasone Propion/Salmeterol54$7,147
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$791$84,42461 claims
PfizerEliquis$37$31,35032 claims
AbbVieQulipta, Linzess$1,665$27,65929 claims
Johnson & JohnsonXarelto$13$12,96314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →